Information Provided By:
Fly News Breaks for July 18, 2017
NKTR
Jul 18, 2017 | 13:50 EDT
JPMorgan analyst Jessica Fye believes this morning's data from Nektar Therapeutics reinforce a differentiated abuse potential for NKTR-181 in an environment where the opioid epidemic is receiving increased regulatory focus. She also sees the data as key for securing a potential partner to help commercialize the pain drug. The analyst thinks Nektar's pipeline over the next 12-18 months has a number of catalysts. She reiterates an Overweight rating on the shares.
News For NKTR From the Last 2 Days
There are no results for your query NKTR